
## **MDHHS – MCIR Release Notes**

Version 2023 - MCIR OLTP 2023 9.6.0 - RFC 220818

Release Date: June 28, 2023

### Forecasting & Assessment Updates (3 items)

 Meningococcal ACWY (MCV4 or MPSV4) CVX 108 should count as dose 1 for 11–13-year-olds. (Ref. #2312)



Correct CVX code 108 counted at age 11 for 1st dose MCV4

Age: 13 years 10 months: Test of over 13 years receiving MCV4 over 13 years of age, forecasting dose 2 at age 16 years.





#### For more information:

IIS: Clinical Decision Support (CDSi) | CDC

Vaccines Required for School Entry in Michigan

Routine Recommendations for Meningococcal Vaccines

Birth-18 Years Immunization Schedule – Healthcare Providers | CDC

# 2. Forecast to "consider' recommendation for PCV20 five years after completion of PCV13/PPSV23 for those who are 65 years and older. (Ref. #2302)

Shared clinical decision-making is recommended regarding administration of PCV20 for adults aged ≥65 years who completed their vaccine series with both PCV13 and PPSV23. Requested an update for PCV20 with updated guidance to provide a "consider" recommendation for PCV20 in MCIR.

Age: 70 years 8 months Tested in UAT:

Pneumococcal Adult	06/01/2020 PCV13 (Prevnar13) 67yrs 8mos	07/05/2021 PPSV23 (Pneumovax) 68yrs 9mos				Consider Next Due 07/05/2026
PCV20		Consider	07/05/20	26 07/05/2026	07/0	05/2026

Forecasting is correct for considering PCV20 in 5 years.

Age: 73y 5m Tested in UAT:

Pneumococcal Adult	06/07/2021 PPSV23 (Pneumovax) 71yrs 5mos	06/14/2023 PCV13 (Prevnar13) 73yrs 5mos		Consider Next Due 06/14/2028
PCV20		Consider	06/14/2028 06/14/2028 06/1	4/2028

This is forecasting correctly for consider in 5 years.

Age: 72 years 5 months Tested in UAT:

Pneumococcal Adult	06/06/2016 PCV13 (Prevnar13) 65yrs 4mos	06/05/2023 PPSV23 (Pneumovax) 72yrs 4mos		Consider Next Due 06/05/2028
PCV20		Consider	06/05/2028 06/05/2028	06/05/2028

This is forecasting correctly for consider in 5 years.

#### For more information:

https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-

timing.pdf?utm campaign=&utm medium=email&utm source=govdelivery

https://www.immunize.org/askexperts/experts pneumococcal vaccines.asp#rec adult

PneumoRecs VaxAdvisor (cdc.gov)

<u>Shared Clinical Decision-Making: PCV20 Vaccination for Adults 65 Years or Older-February 2, 2023 (cdc.gov)</u>

Adult Immunization Schedule - Healthcare Providers | CDC


\_\_\_\_\_



3. All histories of 2 doses of HepB-CpG (Heplisav-B) separated by 4 weeks should be called Series Complete. Histories with 1 HepB adult dose and 1 HepB-CpG (Heplisav-B) dose should forecast another dose and should forecast the 3-dose schedule. (Ref. #1747)

Examples of 3-dose schedule cases:

#### Case 1:




Forecasting for "Hepatitis B" dose 3 at 16 weeks after dose 1 and 8 weeks after dose 2 for Hep B for accelerated, recommended and overdue.

#### Case 2:

	Series Complete
--	--------------------

Accepts HepB (Heplisav-B) as dose 3 of HepB series.

#### Case 3:



Accepts two doses of HepB (Heplisav-B) as Series Complete with two doses at least 4 weeks apart.

#### Case 4:



History of one dose of HepB (Heplisav-B) will forecast Heplisav-B as dose 2 in accelerated and recommended at 4 weeks after dose 1. Overdue is 8 weeks after dose 1.



## General

The FERPA "No Consent" box on Non-Medical Waivers has been removed on Waiver Reports for schools due to the new waiver process. (Ref. #2363)

If you have questions or need assistance, please contact your Field Representative, MCIR Region, or MCIR SOM Help Desk at <a href="mailto:MDHHS-MCIRHelp@michigan.gov">MDHHS-MCIRHelp@michigan.gov</a>.

